MicrosoftLive sourceEvidence: Medium50/100

SOPHiA GENETICS leverages Azure to advance genomic analysis in Italy

SOPHiA GENETICS, in collaboration with Città della Salute e della Scienza di Torino, leverages Microsoft Azure to power its SOPHiA DDM™ platform. This platform enables advanced genomic analysis and precision medicine practices, focusing on cancer and rare diseases. By optimizing workflows and employing AI-powered analytics, the solution enhances researchers' ability to analyze next-generation sequencing (NGS) data. Microsoft Azure provides a secure and scalable cloud infrastructure to manage the vast datasets involved.

Industry
Healthcare
Location
Italy
Published
November 2023

Reported outcomes

Strategic outcomes

New product / capabilityEnabled AI-powered genomic analysisRisk & complianceSecure handling of sensitive patient dataEcosystem & partnershipsImproved data sharing across institutionsNew product / capabilitySupported precision medicine applications
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
Customer
Città della Salute e della Scienza di Torino
Provider
Microsoft
Maturity
Unknown

No explicit deployment-stage evidence found.

Customer identity supportedSource describes one deploymentMaturity evidence evaluated

Primary read

Use case focus

Showing 3 of 3

  • 1genomic analysis
  • 2precision medicine
  • 3biomarker research
  • Efficiently analyze extensive genomic datasets from next-generation sequencing.
  • Ensure secure handling of sensitive patient data.
  • Overcome data silos to facilitate sharing and collaboration.
  • Enable precision medicine to respond to various cancer treatments.
  • Utilized SOPHiA DDM™ Platform powered by Microsoft Azure.
  • Applied artificial intelligence and machine learning to process genomic data.
  • Enabled biomarker research for cancer treatment through NGS analytics.
  • Supported secure cloud-based data storage and sharing with Azure.
Technologies
  • Enhanced research speed and accuracy in analyzing cancer biomarkers.
  • Facilitated precision medicine applications through actionable insights.
  • Improved data management and sharing capabilities across institutions.
  • Strengthened healthcare capabilities using scalable cloud solutions.
Architecture

The SOPHiA DDM™ platform powered by Microsoft Azure leverages AI and machine learning to analyze next-generation sequencing datasets. Researchers analyze tumor samples to generate actionable insights quickly, enabling breakthroughs in precision medicine. Azure ensures secure data ingestion and management.

Sources & evidence1
Evidence: Medium50/100Evidence strength
  • Customer explicitly identified
  • Independent source available
  • Technical implementation details available
  • Recent evidence check available
  • Last evidence check: Jul 22, 2026.
Live sourceStill referenced

The case's original source is still reachable.

  • Cited source last checked Jun 12, 2026 — ok (0/1 broken).

Measures whether this deployment's public evidence persists — not whether the system is still in production.

Type: News ArticlePublished: Nov 28, 2023Publisher: Microsoft News (Switzerland)Evidence: SecondaryConfidence: Low

AI-generated summary. Verify important details with the linked sources before relying on this case.

Explore related AI use cases

Was this useful?

Community

Comments

No published comments yet.